Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Trial Profile

Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Nintedanib (Primary) ; Folic acid; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUME-Lung-2
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2015 No.of arms changed from 2 to 5 as per ClinicalTrials.gov record.
    • 19 Mar 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top